SEYLTX

Ranajoy (Ron) Sarkar Ph.D., MBA is a senior Pharmaceutical and Biotechnology Industry Executive with nearly 2 decades experience in Big Pharma, SMID Cap as well as early-stage Biotech (Forest Laboratories, Actavis, Allergan, Assembly Biosciences and NeuBase Therapeutics). He has held positions of increasing responsibilities in these organizations including roles in the Executive Management Team, Corporate Strategy, BD&L, Global Program Leadership and Product Development. Ron contributed significantly to the Forest Laboratories pipeline, that eventually led to its acquisition by Actavis in a transaction worth over $25B in 2014. In addition, he has been part of over $5B other transactions, ranging from in-licensing, out-licensing, M&A, from both Pharma and Biotech side. He has contributed to 7 INDs, 4 ANDAs and to the development of several commercial products including 2 Blockbuster drugs: Vraylar® (Blockbuster, inventor of the drug product with 2 Orange book patents), Namzaric®, Linzess® (Blockbuster), Viberzi®, Namenda XR®, Viibryd®, Fetzima®. Ron earned his MBA degree from The Wharton School, University of Pennsylvania. He also holds a Ph.D. degree in Pharmaceutics from the University of Georgia working with Dr. James Price. He obtained his undergraduate degree in Pharmacy and Master’s in Pharmaceutics from Jamia Hamdard, the top ranked Pharmacy school in India.